Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey, Abongomera, George, Thomason, Margaret J, Easterbrook, Philippa, Mugyenyi, Peter, Walker, A Sarah, Paton, Nicholas I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739875/
https://www.ncbi.nlm.nih.gov/pubmed/29108797
http://dx.doi.org/10.1016/S1473-3099(17)30630-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739875/
https://www.ncbi.nlm.nih.gov/pubmed/29108797
http://dx.doi.org/10.1016/S1473-3099(17)30630-8

Ejemplares similares